The balance of safety & efficacy: Understanding target antigen density in cancer treatments with the IndEx-2 inducible cell line platform

This year we had the honour of being invited to present in collaboration with Agilent Technologies on SelectScience multiple times. First, we presented our human in vitro T cell exhaustion model and quite recently we had our second webinar together where we discussed our transformational in vitro cell-based platform, IndEx-2.

In this webinar, one of the inventors of IndEx-2, Dr Timothy London, Scientific Director of Molecular Biology at RoukenBio presents IndEx-2, our transformational in vitro cell-based platform engineered to modulate the expression of one or two target antigens across a range of biologically relevant levels. 

RoukenBio's IndEx-2 and Agilent's instrumentation

By integrating IndEx-2 with tools such as the Agilent xCELLigence Real Time Cell Analyzer (RTCA), NovoCyte Flow Cytometer, and cytokine release measurement protocols, the antigen density thresholds required for the activation of potential immunotherapeutic candidates can be determined.

Importantly, this comprehensive approach caters to a diverse array of functional readouts, spanning from cytotoxic responses to immune cell activation. This way IndEx-2 can be easily integrated with immune-oncology primary cell assays, to provide a complete picture of a targeted drug candidate’s mechanism of action and safety profile.

Let’s look further into this powerful cell line system as presented by our Scientific Director of Molecular Biology, Dr. Timothy London: watch our video.

Stay tuned to our blog for the most up-to-date news and a wealth of additional scientific resources.